🇺🇸 Low Molecular Weight Heparin in United States

850 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Off Label Use — 228 reports (26.82%)
  2. Haemorrhage — 157 reports (18.47%)
  3. Foetal Exposure During Pregnancy — 87 reports (10.24%)
  4. Premature Baby — 76 reports (8.94%)
  5. Exposure During Pregnancy — 58 reports (6.82%)
  6. Maternal Exposure During Pregnancy — 55 reports (6.47%)
  7. Anaemia — 52 reports (6.12%)
  8. Death — 49 reports (5.76%)
  9. Premature Delivery — 44 reports (5.18%)
  10. Product Use In Unapproved Indication — 44 reports (5.18%)

Source database →

Low Molecular Weight Heparin in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Low Molecular Weight Heparin approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Low Molecular Weight Heparin in United States?

Yangzhou University is the originator. The local marketing authorisation holder may differ — check the official source linked above.